American Association for Study of Liver Diseases: Rapid Response for Once-Daily Protease Inhibitor, University of North Carolina Study
MedPageToday -- BOSTON -- The vast majority of patients with hepatitis C virus infection respond rapidly to a novel, once-daily protease inhibitor that may also mitigate the effects of a mutation predicting worse response to standard combination therapy, researchers reported here.